Data from the Phase IIb/III trial demonstrated oral once daily blarcamesine pre-specified clinical efficacy through upstream SIGMAR1 activation.

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb ...

GeniPhys, a preclinical-stage company developing regenerative biomaterials for soft tissue restoration, has been awarded a $500,000 NSF SBIR Phase IIB supplemental funding grant.